Exploring What Does Deruxtecan Do? The Mechanism Behind a Modern Cancer Payload
•
3 min read
First approved by the U.S. Food and Drug Administration (FDA) in 2019 as a component of the drug Enhertu, deruxtecan serves as the highly potent cytotoxic payload within several advanced antibody-drug conjugates (ADCs). These conjugates, which specifically target cancer cells, represent a major advancement in targeted chemotherapy by delivering a powerful cell-killing agent directly to the tumor. The question, 'what does deruxtecan do?', is fundamentally about understanding this sophisticated delivery and attack system.
